Last reviewed · How we verify
Oral Casopitant (GW679769)
Oral Casopitant (GW679769) is a NK1 receptor antagonist Small molecule drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.
Casopitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.
At a glance
| Generic name | Oral Casopitant (GW679769) |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor (neurokinin-1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Casopitant selectively antagonizes the NK1 receptor, which is a key mediator of nausea and vomiting signals in the central nervous system. By blocking substance P binding to NK1 receptors in brain regions controlling emesis, it prevents both acute and delayed chemotherapy-induced nausea and vomiting (CINV). This mechanism complements 5-HT3 antagonists and corticosteroids used in standard antiemetic regimens.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
Common side effects
- Headache
- Constipation
- Dizziness
- Fatigue
Key clinical trials
- Cyclophosphamide Drug Interaction Study In Cancer Patients (PHASE1)
- A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults (PHASE1)
- Observational Study Evaluating The Processing Or Breakdown Of GW679769 In Subjects With Hepatic Impairment (PHASE1)
- A Study in Healthy Subjects to Assess How Dosing of Rifampin Affects What the Body Does to a Dose of GW679769 (Casopitant). (PHASE1)
- Study Of Healthy Subjects To Assess The Effect Of Ketoconazole And The Way The Body Will React To Casopitant [GW679769] (PHASE1)
- A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy (PHASE3)
- A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers (PHASE1)
- Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral Casopitant (GW679769) CI brief — competitive landscape report
- Oral Casopitant (GW679769) updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Oral Casopitant (GW679769)
What is Oral Casopitant (GW679769)?
How does Oral Casopitant (GW679769) work?
What is Oral Casopitant (GW679769) used for?
Who makes Oral Casopitant (GW679769)?
What drug class is Oral Casopitant (GW679769) in?
What development phase is Oral Casopitant (GW679769) in?
What are the side effects of Oral Casopitant (GW679769)?
What does Oral Casopitant (GW679769) target?
Related
- Drug class: All NK1 receptor antagonist drugs
- Target: All drugs targeting NK1 receptor (neurokinin-1 receptor)
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy
- Compare: Oral Casopitant (GW679769) vs similar drugs
- Pricing: Oral Casopitant (GW679769) cost, discount & access